Skip to content

Evaluation of Systolic Function in Heart Failure With Middle Ejection Fraction by 3D Speckle Tracking Imaging

Evaluation of Left Ventricular Systolic Function in Heart Failure With Middle Ejection Fraction by 3D Speckle Tracking Imaging

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04949997
Enrollment
130
Registered
2021-07-02
Start date
2017-10-01
Completion date
2019-05-31
Last updated
2021-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Keywords

median ejection fraction, 3D-STI

Brief summary

In 2016, the European Heart Association defined the median ejection fraction heart failure for the first time. More research is needed to improve our understanding of this population, so as to make the best clinical decision and improve the prognosis. In this study, 3D-STI was used to evaluate left ventricular systolic function in heart failure with median ejection fraction.

Detailed description

As the final manifestation of cardiovascular disease and the main cause of death, heart failure is one of the important challenges threatening human health in the 21st century. In 2016, the European Heart Association proposed a new classification standard for heart failure. In particular, for the first time, heart failure with median ejection fraction has been clearly defined. These patients have received more and more attention, but there are still relatively few studies on them. More research is needed to improve our understanding of this part of the population in order to make the best clinical decisions and improve the prognosis. 3D speckle tracking technology is a new technology developed on the basis of real-time three-dimensional echocardiography and speckle tracking technology. It is gradually recognized in the evaluation of left ventricular systolic and diastolic function, especially in the evaluation of cardiotoxicity of chemotherapy drugs. At present, the application of 3D-STI in the evaluation of left ventricular systolic function in heart failure with median ejection fraction is limited and needs further study.In this study, 3D-STI was used to evaluate left ventricular systolic function in heart failure with median ejection fraction.

Interventions

HF was divided into HF with preserved ejection fraction, HF with median ejection fraction and HF with reduced ejection fraction.

Sponsors

Peking University Third Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

Meeting the diagnostic and classification criteria of heart failure proposed in the 2016 ESC guidelines for the diagnosis and treatment of acute / chronic heart failure

Exclusion criteria

1. acute or chronic infectious diseases; 2. COPD, chronic bronchitis, emphysema and other serious lung diseases; 3. Autoimmune diseases; 4. Malignant tumor; 5. Acute, chronic liver disease or other reasons lead to abnormal liver function (transaminase is more than 3 times of normal value); 6. Acute and chronic kidney disease, end-stage renal disease (serum creatinine \> 220 μmol/L, or creatinine clearance rate \< 30 ml/min); 7. Heart valve disease; 8. Severe arrhythmia; 9. The image quality of echocardiography was poor when it was larger than three sections;

Design outcomes

Primary

MeasureTime frameDescription
3D-STI measurement indexesone weekstrain values of different sections from 3D-STI

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026